verb \ pruh-tay-go\ latin “to protect”
Praetego is a pharmaceutical company committed to improving health by addressing chronic diseases of aging, starting with Alzheimer’s disease. Praetego’s novel small molecules (the Amadorins) have a multifunctional mechanism of action with the potential to provide systemic protection against neurodegenerative disease.
Praetego was founded on rigorous science and a desire to offer a clinical meaningful treatment for debilitating diseases of aging. Our technology inhibits a common driver shared by neurodegeneration, diabetic microvascular disease, and aging. Inhibiting this driver at the initial step could radically impact of Alzheimer’s Disease and other neurodegenerative disorders.
Praetego’s leadership team led the discovery and development of the Amadorins. Along with industry veterans, the team brings extensive technical and operational experience in developmental stage drug companies. Our disease area experts provide timely guidance to expedite the development of our candidates toward clinical value.
Read More >
Praetego’s novel small molecules have demonstrated preclinical proof of efficacy in a variety of neurodegenerative and diabetic microvascular disease models. Our Alzheimer's Disease program leads the pipeline and is complemented by our research in Diabetic Peripheral Neuropathy and Diabetic Retinopathy, both implicated in neurodegeneration.
September 30, 2021
Praetego wins Innovator’s Pitch Challenge at RESI Longevity
July 14, 2021
After being a winner in the Digital RESI June Innovator’s Pitch Challenge, Praetego’s CEO Pepper Landson is interviewed by Life Science Nation to tell her story.
